The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma.In this first-in-human study, up to 10 cycles of AMG 420 were given (4-week infusions/6-week […]
Recent Content
- FDA grants orphan drug status to new treatment for agressive blood cancers
- FDA gives green light to first human trial testing cancer drug GTB-5550
- Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma
- (no title)
- (no title)
- Scientists test treatment strategy using ‘glioblastoma on a chip’
- (no title)
- (no title)
- (no title)
- Prostate cancer tool may cut risk for women in radiation therapy